UK Into 2019: Health-Tech Adoption Not Far From The 'Tipping Point'

 
• By Ashley Yeo
  
Generate a summary of this article
Listen to this article
Beta

The UK's future economic relationship with the EU consumed more than its fair share of headlines in 2018. But within UK health care, at ground level, Brexit was often missing entirely from main conference agendas, as stakeholders sought to both maximize current operating conditions and prepare for future health-care architectures and evolving innovation systems. That was the case at Medtech Futures, in Cambridge, UK, this fall.

uk flag close up

As 2018 turns to 2019, the future may be unpredictable for those working in the UK health-care ecosystem, with budgetary pressures on the system higher than ever, greater demand for services, the unknown perils of Brexit and the associated talent shortage, and systemic care staff shortages. That is not to mention a whole new regulatory system for medical technology in the EU, of which, at the time of writing, the UK still remains a part.

Nevertheless, in this fog of uncertainty, there remain bright spots for UK health-care stakeholders, as both industry and the government...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from United Kingdom

Global Medtech Guidance Tracker: September 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Abbott’s Share-Gobbling Aveir DR Leadless Pacing System Introduced To UK

 
• By Natasha Barrow

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Global Medtech Guidance Tracker: August 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Nearly 80 documents have been posted on the tracker since its last update.

More from Europe

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Abbott’s Share-Gobbling Aveir DR Leadless Pacing System Introduced To UK

 
• By Natasha Barrow

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Amferia Aims To Bring Peptide Hydrogel To Fight Against Antimicrobial Resistance

 
• By Natasha Barrow

Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.